**Author details**

Jianu Catalin1,2\*, Jianu Silviana3 and Barsan Claudia2

1 Department of Neurology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania

2 Department of Neurology, Clinical Emergency County Hospital, Timisoara, Romania

3 Department of Ophthalmology, Military Emergency Hospital, Timisoara, Romania

\*Address all correspondence to: dcjianu@yahoo.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**101**

1997;**244**:112-118

*Clinical Presentation of Myasthenia Gravis DOI: http://dx.doi.org/10.5772/intechopen.86566*

[1] Daroff RB, Jankovic J, Mazziotta JC, Scott L, editors. Bradley's Neurology in Clinical Practice. London, New York, Oxford, Philadephia, St. Louis, Sydney, Toronto: Elsevier; 2016. ISBN: 978-0-323-28783-8. Pomeroy Seventh

[10] Myasthenia Gravis Foundation of America. Myasthenia Gravis: A Manual for the Health Care Provider. 2008. Available from: http://www. myasthenia.org/docs/MGFA\_ ProfessionalManual.pdf

[11] Grob D. Course and management

[12] Koopman WJ, Wiebe S, Colton-Hudson A, Moosa T, Smith D, Bach D, et al. Prediction of aspiration in myasthenia gravis. Muscle & Nerve.

[13] Romi F, Skeie GO, Gilhus NE. Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance. Archives of Neurology.

[14] Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. The Annals of Thoracic

Surgery. 2000;**70**(1):327-334

Neurology. 2003;**60**:243-248

2010;**23**(5):530-535

2006;**223**:81-83

[16] Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Current Opinion in Neurology.

[17] Bau V, Hanisch F, Hain B, Zierz S. Ocular involvement in MuSK antibodypositive myasthenia gravis. Klinische Monatsblätter für Augenheilkunde.

[15] Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Archives of

of myasthenia gravis. JAMA.

1953;**153**:529-532

2004;**29**(2):256-260

2005;**62**(3):442-446

[2] Angelini C, Martignago S, Biscigli M, Albertini E. Myasthenia gravis with anti-MuSK antibodies: Clinical features and histopathological changes. In: Pruitt JA, editor. A Look into Myasthenia Gravis. Rijeka: InTech; 2011. ISBN

[3] Trouth AJ, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: A review. Autoimmune Disease.

[4] Clarke C, Howard R, Rossor M, Shorvon S, editors. Neurology: A Queen Square Textbook. Oxford: Blackwell Publishing Ltd.; 2009. ISBN:

[5] Engel AG, editor. Myasthenia Gravis and Myasthenic Disorders. Oxford: Oxford University Press; 2012. ISBN-13:

[6] Kaminski HJ. Myasthenia Gravis and Related Disorders. Totowa, New Jersey: Humana Press Inc; 2003. ISBN

[7] Scherer K, Bedlack RS, Simel DL. Does this patient have myasthenia gravis? JAMA. 2005;**293**(15):1906-1914

[8] Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle & Nerve. 2008;**37**(2):141-149

[9] Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: Diagnosis and follow-up of 100 consecutive patients. Journal of the Neurological Sciences.

Edition

**References**

978-953-307-821-2

2012;**2012**:874680

978-1-405-13443-9

9780199738670

1-58829-058-1

*Clinical Presentation of Myasthenia Gravis DOI: http://dx.doi.org/10.5772/intechopen.86566*
